AppYea, Inc. (APYP)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
AppYea, Inc. (APYP) trades at $0.01 with AI Score 50/100 (Grade B). AppYea, Inc. is a digital health company specializing in sensor monitoring and software solutions for snoring and sleep apnea. Market cap: $6.03M, Sector: Technology.
Price live · AI analysis from Mar 15, 2026Analyst Coverage for APYP: APYP does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates APYP against Technology peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
APYP: 3/7 perspectives are bearish. Dominant signal: Ken Griffin bearish.
How is this calculated? →AppYea, Inc. (APYP) Technology Profile & Competitive Position
AppYea, Inc. develops and patents digital health solutions for sleep apnea and snoring, focusing on sensor-based monitoring and real-time detection. Their SleepX app and DreamIT wristband aim to provide accessible and convenient sleep disorder management, positioning them in the growing market for digital health technologies.
What Is the Investment Thesis for APYP?
AppYea, Inc. presents a focused investment opportunity within the digital health sector, specifically targeting the sleep apnea and snoring market. With a market capitalization of $6.03M and a gross margin of 15.8%, the company is positioned to capitalize on the increasing demand for accessible and convenient sleep monitoring and treatment solutions. Key value drivers include the continued development and refinement of their SleepX and DreamIT product lines, expansion into new markets, and potential partnerships with healthcare providers. The company's low beta of 0.11 suggests relatively low volatility compared to the broader market. However, investors should be aware of the risks associated with investing in OTC-listed companies and the competitive landscape of the digital health market.
Based on FMP financials and quantitative analysis
APYP Key Highlights
- Market capitalization of $6.03M, reflecting its current valuation in the OTC market.
- Gross margin of 15.8%, indicating the profitability of its products before operating expenses.
- Free cash flow of $-0.00B, highlighting the need for careful cash management and potential future financing.
- Beta of 0.11, suggesting lower volatility compared to the overall market.
- Focus on the digital health market for sleep apnea and snoring, addressing a significant and growing health concern.
Who Are APYP's Competitors?
APYP is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| NOW ServiceNow, Inc. | $108.69 | +2.23% | $112.09B | 71 |
| RSASF RESAAS Services Inc. | $0.30 | +2.76% | $25.04M | 69 |
| CSAI Cloudastructure Inc. | $0.36 | +0.47% | $6.84M | 68 |
| PDFS PDF Solutions, Inc. | $56.75 | -4.11% | $2.34B | 68 |
| USER UserTesting, Inc. | $7.50 | -0.13% | 63 | |
| JAXAF Vinyl Group Ltd | $0.05 | +0.00% | $74.16M | 63 |
| RCT RedCloud Holdings plc | $0.24 | +0.13% | $10.78M | 63 |
| XM Qualtrics International Inc. | $18.15 | +0.06% | $11.01B | 63 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are APYP's Key Strengths?
- Proprietary technology for sleep monitoring and treatment.
- Integrated solution combining app and wearable device.
- Focus on the growing market for digital health solutions.
- Low beta indicating lower volatility.
What Are APYP's Weaknesses?
- Limited financial resources.
- Small number of employees.
- Dependence on single product line.
- OTC listing presents liquidity and regulatory challenges.
What Could Drive APYP Stock Higher?
- Potential partnerships with healthcare providers and sleep clinics.
- Continued development and refinement of SleepX and DreamIT product lines.
- Expansion into new geographic markets.
- Increased adoption of telehealth and remote patient monitoring.
What Are the Key Risks for APYP?
- Financial-distress signal — its Altman Z-Score of -5.28 sits in the distress zone (elevated bankruptcy risk).
- Competition from established medical device companies.
- Technological obsolescence.
- Limited financial resources.
- OTC listing presents liquidity and regulatory challenges.
- Regulatory changes in the healthcare industry.
What Are the Growth Opportunities for APYP?
- Expansion into New Markets: AppYea can expand its market reach beyond its current base by targeting new geographic regions and demographic segments. The global market for sleep apnea devices is projected to reach billions of dollars, offering significant growth potential for AppYea's SleepX and DreamIT products. Timeline: Ongoing.
- Strategic Partnerships: Collaborating with healthcare providers, sleep clinics, and insurance companies can accelerate adoption of AppYea's solutions and increase market penetration. Partnerships can provide access to established distribution channels and patient networks. Timeline: Ongoing.
- Product Innovation: Continuous innovation and development of new features for the SleepX and DreamIT product lines can enhance their value proposition and attract new customers. This includes incorporating advanced sensor technologies, AI-powered analytics, and personalized treatment plans. Timeline: Ongoing.
- Direct-to-Consumer Marketing: Implementing targeted marketing campaigns to reach consumers directly through online channels, social media, and digital advertising can increase brand awareness and drive sales. This approach allows AppYea to bypass traditional healthcare channels and reach a wider audience. Timeline: Ongoing.
- Integration with Telehealth Platforms: Integrating AppYea's solutions with telehealth platforms can provide remote monitoring and treatment options for patients with sleep apnea and snoring. This integration can enhance patient engagement and improve treatment outcomes. Timeline: Ongoing.
What Opportunities Does APYP Have?
- Expansion into new geographic markets.
- Strategic partnerships with healthcare providers.
- Development of new features and products.
- Increased adoption of telehealth and remote patient monitoring.
What Threats Does APYP Face?
- Competition from established medical device companies.
- Technological obsolescence.
- Regulatory changes in the healthcare industry.
- Economic downturn affecting consumer spending.
What Are APYP's Competitive Advantages?
- Proprietary Algorithms: Unique algorithms for monitoring breathing and detecting snoring/sleep apnea events.
- Patented Technology: Designs and patents for sensor monitoring and software solutions.
- Integrated Solution: Combination of smartphone application and wearable device for comprehensive sleep monitoring and treatment.
What Does APYP Do?
Founded in 2012 and based in Rehovot, Israel, AppYea, Inc. operates as a digital health company focused on designing, patenting, and producing sensor monitoring and software solutions for snoring and sleep apnea. The company's core product offerings include the SleepX App and DreamIT wristband. The SleepX App is a smartphone application that employs unique algorithms to monitor breathing and detect snoring events in real time. Complementing the app, the DreamIT wristband features various sensors and interfaces with the SleepX App to provide treatment for snoring. AppYea also offers SleepX PRO, an application designed to monitor breathing and detect sleep apnea incidents, and DreamIT PRO, a wristband that interfaces with the SleepX PRO app for sleep apnea treatment. AppYea aims to provide accessible and convenient solutions for individuals suffering from sleep-related breathing disorders, leveraging technology to improve sleep quality and overall health.
What Products and Services Does APYP Offer?
- Designs and patents sensor monitoring solutions.
- Develops software for snoring and sleep apnea detection.
- Produces the SleepX App for real-time snoring monitoring.
- Manufactures the DreamIT wristband for snoring treatment.
- Offers SleepX PRO for sleep apnea detection.
- Provides DreamIT PRO for sleep apnea treatment.
How Does APYP Make Money?
- Develops and sells sensor-based monitoring devices (DreamIT wristband).
- Offers smartphone applications (SleepX App, SleepX PRO) for sleep monitoring and treatment.
- Generates revenue through direct sales to consumers.
- Potential for future revenue through partnerships with healthcare providers and insurance companies.
What Industry Does APYP Operate In?
AppYea, Inc. operates within the rapidly expanding digital health market, specifically targeting sleep apnea and snoring solutions. The industry is characterized by increasing adoption of telehealth and remote patient monitoring technologies. The competitive landscape includes established medical device companies, as well as emerging digital health startups. AppYea's focus on sensor-based monitoring and smartphone integration positions it to capitalize on the growing demand for accessible and convenient sleep disorder management.
Who Are APYP's Key Customers?
- Individuals suffering from snoring.
- Individuals suffering from sleep apnea.
- Healthcare providers seeking remote patient monitoring solutions.
- Sleep clinics and sleep disorder centers.
Company Profile
AppYea, Inc. operates in the Software - Application industry within the Technology sector. It is headquartered in Gan Yavne, IL. The company is led by CEO Yakir Abady. APYP has traded publicly since 2014.
F-Score 4/9Financial Health
AppYea, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -5.28 places it in the distress zone, a signal of elevated financial risk.
Key Financial Metrics
Return on assets is -76.6%, showing how much profit it generates from its asset base. Its free cash flow yield is -17.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.10 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -190.9%, the inverse of the P/E and a quick read on earnings relative to price.
APYP Valuation & Market Position
With a $6.03M market cap, AppYea, Inc. sits in the micro-cap segment of the market. Relative to its peer group, APYP's quantitative score of 50/100 is below the peer average of 68/100.
APYP Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in APYP's future, indicating that those closest to the company believe in its potential.
- Community sentiment has shifted positively, with discussions highlighting APYP's innovative projects and growth strategy.
- Market perception has been bolstered by recent partnerships that could enhance APYP's market position and revenue streams.
- The overall industry outlook appears favorable, with increasing demand for APYP's services, attracting more investor interest.
Bear Case
- Concerns have emerged regarding APYP's competitive positioning, with some analysts questioning its ability to maintain market share.
- Negative community sentiment has been noted, particularly around execution risks associated with new initiatives.
- Insider selling activity has raised eyebrows, suggesting some lack of confidence among executives about the company's short-term prospects.
- Recent regulatory changes in the industry may pose challenges for APYP, potentially impacting its operational flexibility.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · January 2026
APYP Latest News
No recent news available for APYP.
APYP Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for APYP.
Price Targets
Wall Street price target analysis for APYP.
APYP MoonshotScore
What does this score mean?
The MoonshotScore rates APYP's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Yakir Abady
CEO
Yakir Abady serves as the CEO of AppYea, Inc. His background includes experience in managing and leading technology-driven companies. He is responsible for overseeing the company's strategic direction, product development, and overall operations. His leadership is focused on driving innovation and growth in the digital health market, particularly in the area of sleep apnea and snoring solutions.
Track Record: Under Yakir Abady's leadership, AppYea, Inc. has focused on developing and commercializing its SleepX and DreamIT product lines. Key milestones include securing patents for its sensor monitoring technology and expanding its market reach through online channels. He is currently focused on securing partnerships to expand market reach.
APYP OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that AppYea, Inc. may not meet the minimum financial or reporting requirements for higher tiers like OTCQB or OTCQX. Companies in this tier often have limited operating history, minimal assets, or may be undergoing financial distress. Investing in OTC Other stocks carries significant risks due to the lack of regulatory oversight and transparency compared to NYSE or NASDAQ-listed companies. Investors should exercise extreme caution and conduct thorough due diligence before investing in OTC Other securities.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited Liquidity: Low trading volume and wide bid-ask spreads can make it difficult to buy or sell shares.
- Lack of Transparency: Limited financial reporting and regulatory oversight increase the risk of fraud and manipulation.
- Financial Instability: Companies in the OTC Other tier may be financially distressed or have limited operating history.
- Dilution Risk: Frequent stock dilutions can significantly reduce the value of existing shares.
- Regulatory Scrutiny: OTC-listed companies are subject to less regulatory scrutiny than exchange-listed companies.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's capital structure and potential for dilution.
- Review the company's legal and regulatory compliance.
- Check for any red flags or warning signs in the company's history.
- Understand the risks associated with investing in OTC-listed companies.
- Patents for sensor monitoring technology.
- Development of SleepX and DreamIT product lines.
- Focus on the growing market for digital health solutions.
APYP Technology Stock FAQ
What does AppYea, Inc. do?
AppYea, Inc. is a digital health company that specializes in developing and marketing sensor-based monitoring and software solutions for individuals suffering from snoring and sleep apnea. The company's core products include the SleepX App and DreamIT wristband, which work together to monitor breathing patterns, detect sleep disturbances, and provide real-time feedback. By leveraging technology to address sleep-related breathing disorders, AppYea aims to improve sleep quality and overall health for its customers.
What do analysts say about APYP stock?
As of 2026-03-15, there is limited analyst coverage available for APYP stock due to its OTC listing and small market capitalization. Investors should conduct their own thorough research and due diligence before investing in APYP. Key valuation metrics to consider include the company's gross margin of 15.8% and its free cash flow of $-0.00B. Growth considerations include the company's potential to expand into new markets and develop new products.
What are the main risks for APYP?
Investing in AppYea, Inc. carries several risks, including limited liquidity due to its OTC listing, competition from established medical device companies, and the potential for technological obsolescence. The company's small size and limited financial resources also present challenges. Additionally, regulatory changes in the healthcare industry could impact the company's business model and profitability. Investors should carefully consider these risks before investing in APYP.
What are the key factors to evaluate for APYP?
AppYea, Inc. (APYP) holds an AI score of 50/100 (moderate). Not financial advice.
How frequently does APYP data refresh on this page?
APYP prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven APYP's recent stock price performance?
AppYea, Inc. (APYP) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary technology for sleep monitoring and treatment. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider APYP overvalued or undervalued right now?
Valuing AppYea, Inc. (APYP) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying APYP?
Before investing in AppYea, Inc. (APYP), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data as of 2026-03-15.
- OTC market data may be limited or unreliable.
- Analyst coverage may be limited due to the company's size and OTC listing.